Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $224.30M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.45M
Average 0.49M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +71.2% | +12.4% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +71.2% over three years. Forward estimates point to Revenue at +12.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
KalVista Pharmaceuticals, Inc. NASDAQ:KALV | $1.44B | $27.00 | Not rated | -9.9 | +89.21% |
Omeros Corporation NASDAQ:OMER | $1.27B | $17.49 | Not rated | 8.4 | +63.76% |
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | $796.97M | $1.79 | Not rated | -30.5 | +21.09% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | +6.94% |
Prothena Corporation plc NASDAQ:PRTA | $419.01M | $8.16 | Not rated | -3.1 | -20.27% |
Fulcrum Therapeutics, Inc. NASDAQ:FULC | $287.64M | $3.77 | Not rated | -3.6 | -61.46% |
ADC Therapeutics S.A. NYSE:ADCT | $171.07M | $1.34 | Not rated | -1.2 | -66.25% |
Compass Therapeutics, Inc. NASDAQ:CMPX | $139.35M | $0.77 | Not rated | -5.5 | -87.69% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -87.42% |
Continue the stock analysis
Jump to another research area for this company.